faqir.eu

What It Is

FAQIR Institute is a European health data company founded in 2022 and based in Ghent, Belgium. Its goal is to make health data scattered across registries, hospital systems, research environments, apps, devices, and sensors discoverable, trustworthy, and easy to use. It forms an ecosystem together with FAQIR Foundation and the product platform Qwenda: the Foundation handles the nonprofit mission and patient-centered principles, the Institute provides tools, support, and implementation, and Qwenda serves as the patient-centered data platform for real-world use.

Core Capabilities

Its methodology is built on the FAIR principles with the addition of Quality: Findable, Accessible, Quality, Interoperable, Reusable. Qwenda emphasizes that patients have their own personal data space, can access data from different sources, and decide with whom to share it and for how long; they can also change those decisions at any time. The platform also focuses on use across systems and organizations, supporting long-term reuse of structured data. Examples on the official website include modules such as Patients, Cohorts, Studies, FAIR Audit, federated nodes, and consent events, along with use cases such as hemophilia registries, obesity, vaccine monitoring, rare immune networks, and clinical trial cohorts.

Pricing and Deployment

The official website does not disclose plans, pricing, a free tier, or trial information, nor does it explain the procurement process. For deployment, the site only shows app.qwenda.com and multiple federated nodes online, which is not enough to determine whether it supports pure cloud, self-hosted, or hybrid deployment. APIs, SDKs, developer documentation, and a concrete list of third-party integrations are also not publicly available.

Pros and Cons

Its strengths are its highly vertical positioning, making it suitable for complex scenarios such as medical data governance, research collaboration, and patient-authorized sharing. Its emphasis on data quality, traceability, interoperability, and reuse aligns well with the requirements of medical research for trusted data. Its patient-first and consent-management design also fits the direction of European health data governance. The main weaknesses are limited transparency around commercial information, and missing details on security and compliance certifications, permission models, integration methods, and technical architecture. Organizations should conduct further due diligence before enterprise procurement.

Who It’s For and Access from China

It is better suited to European hospitals, research networks, patient organizations, public health projects, and clinical cohort teams. Chinese organizations considering it should carefully evaluate medical data compliance, cross-border data transfer, integration with local systems, and language localization. Access from China is not indicated in the available text, so its status is unknown.